A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.

ABSTRACT:

Introduction

Lurbinectedin is a selective inhibitor of oncogenic transcription U.S. Food and Drug Administration (FDA)-approved for patients with relapsed small cell lung cancer (SCLC) as monotherapy at 3.2 mg/m² every 3 weeks (q3wk). ATLANTIS was a phase 3 study in SCLC with lurbinectedin 2.0 mg/m² plus doxorubicin 40 mg/m² q3wk vs physician's choice, with overall survival (OS) as the primary endpoint and objective response rate (ORR) as the secondary endpoint. This work aimed to dissect the contribution of lurbinectedin and doxorubicin to antitumor effects in SCLC, and to predict the efficacy of single-agent lurbinectedin at 3.2 mg/m² in ATLANTIS to allow for a head-to-head comparison with the control arm.

Methods

The dataset inc

SUBMITTER: Fudio S 

PROVIDER: S-EPMC10311440 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature